Library Progress International
Vol.44 No.3, Jul-Dec 2024: P.7070-7082

Print version ISSN 0970 1052
Online version ISSN 2320 317X

Original Article

Available online at www.bpasjournals.com

Role of Artificial Intelligence (AI) and Intellectual Property Rights (IPR) in Transforming Drug Discovery and Development in the Life Sciences: Legal and Ethical Concerns

Sahil Lal[1], Prof. (Dr.) Bhupinder Singh[2], Prof. (Dr.) Christian Kaunert[3]

[1]Research Scholar, Sharda School of Law, Sharda University, India.
adv.sahillal@gmail.com
ORCID: https://orcid.org/0000-0001-9827-3717
[2]Professor, School of Law, Sharda University, India.
bhupinder.singh@sharda.ac.in
ORCID: https://orcid.org/0009-0006-4779-2553
[3]Dublin City University, Ireland & University of South Wales, UK
ORCID: https://orcid.org/0000-0002-4493-2235

How to cite this article: Sahil Lal, Bhupinder Singh, Christian Kaunert (2024) Role of Artificial Intelligence (AI) and Intellectual Property Rights (IPR) in Transforming Drug Discovery and Development in the Life Sciences: Legal and Ethical Concerns. *Library Progress International,* 44(3), 7070-7082.

ABSTRACT

Artificial intelligence (AI) marks a sea change for the life sciences industry with recent advances in drug discovery and development. Harnessing the capabilities of state-of-the-art computational methods can accelerate the identification of new drug candidates and chemical scaffolds, in addition to expediting multiple elements of downstream pharmaceutical processes. Now, with this technological revolution comes a lucratively-controversial maze of intellectual property rights (IPR) and ethical hurdles woven throughout. These research paper discusses more than the current perspective to AI influence in changing drug discovery by cantering on its mutual legal and ethical implications. It provides object insight the usage of AI in drug discovery, preserving predictive analytics, chemical optimization, and clinical trial design. This is followed by a study of the IPR framework related to the life sciences industry with focus on challenges posed by AI-generated inventions and necessity for patent eligibility and ownership in technology. Ethical considerations are also central with data privacy, algorithmic bias and development of strong ethical guidelines being discussed for responsible use on an AI in healthcare. Stakeholders' pharmaceutical companies, regulatory agencies, healthcare providers and patient advocacy groups need to work together in addressing these concerns, the paper stresses. Finally, the paper offers policy recommendations focused on areas for improvement including: (a) clarifying regulatory guidance (b) advocating data governance and ethics AI research. Dealing with these challenges (almost) head-on ensures that the promise AI holds can be properly exploited in life sciences without compromises to standards of legality or ethics.

Keywords: Artificial Intelligence, Drug Discovery, Intellectual Property Rights, Legal Implications, Ethical Concerns, Pharmaceutical Industry.

1. Introduction

In recent years, the pharmaceutical industry has undergone a tremendous transformation; one of these transformations was in drug discovery that happened due to integration with artificial intelligence (AI) technologies. AI algorithms are promising to make all stages within drug development ranging from identification of potential therapeutics, chemical optimization, and efficacy/toxicity prediction more efficient [1]. AI, using large data sets and computational techniques, can reduce the time to market of traditional drug discovery as well their related costs [2].

The addition of artificial technology has proven on average, to allow drug discovery pipelines for a preclinical phase within 4 years while the traditional timeline is between five and six years [3]. This faster path has the potential to significantly impact on drug development in the pharma industry, helping new therapies reach patients

more quickly and address actual medical needs better than ever [4].

1.1 Significance of IPR in Life Sciences

Intellectual property rights (IPR) are especially important for innovations in the life sciences arena, particularly those related to drug discovery and development [5]. Patents are the lifeblood of exclusivity around their new drug candidates, and give them exclusive rights to sell stomping on generics for several years while they recoup all that R&D investment [6]. The growing use of AI in drug discovery is posing ownership and IP challenges around the patentability for inventions generated by or with AI [7]. And court decisions have confirmed that AI cannot be designated an inventor under existing patent law, as seen in Thaler v. Vidal. These findings highlight the potential for AI-discovered drugs to be ineligible subject matter under current patent laws, and therefore could pose serious questions around whether this approach will have any impacts on Big Pharma being able to protect their intellectual property rights in a manner that encourages further innovation [8].

1.2 Legal and Ethical Concerns Addressed

We must consider that the use of AI and machine learning within drug discovery brings several legal and ethical challenges for all interested parties in the pharmaceutical sector [9]. These concerns can include but are not limited to:

a. Patent Eligibility & Ownership- Deciding practice on the patent eligibility and ownership frame work for adjudging and safeguarding standpoints of who owns, AI related invention in Pharma [10].
b. Liability: Lastly, if there are side effects of AI-created drugs how will the responsibility be assigned and what would be its legal backlash.
c. However, AI in drug discovery should comply with existing regulations and guidelines established by the regulatory agencies such as FDA (Food & Drug Administration) or EMA [11].
d. Data privacy and patient consent: Generating drug leads from AI-driven analysis of patient data raises ethical issues around safeguarding personal information, ensuring individuals can give their informed agreement freely (informed consents), and avoiding unfair treatment according to genetic profiles [12].
e. Governance (e.g., ethical frameworks): Clear rules should be established regarding the development and implementation of AI in Pharma for responsible innovation, public trust [13].

The research examines the intersection between AI, IPR in drug discovery and development analysing comprehensively a new wave of transformation with some pragmatic issues and legal aspects to fulfil this ambitious claim [14]. This paper therefore aims to provide insight for policymakers, industry stakeholders and society in general on the implications of AI-driven innovation addressing drug discovery that have already come into reality while highlighting policy challenges through considering them against current IPR framework.

2. Artificial Intelligence in Drug Discovery

At its most basic, artificial intelligence (AI) is the field of computer science that allows machines to do things which would normally require human thinking - learning new concepts, solving problems and even making decisions. AI in drug discovery uses cutting-edge computational methods - like Machine Learning (ML) and Deep learning (DL), to speed up, optimize different phases of the development process [15]. Machine learning algorithms learn from data and form predictions or decisions without being instructed to do so. Typically, these are supervised learning, unsupervised learn and reinforcement etc. Supervised learning is the algorithm performing classification or prediction on input data, Unsupervised learning: involves finding structure in unlabelled data. This is Reinforcement learning, wherein an agent interacts with the environment and gets rewarded (punished) to discover optimal actions [16]. Deep learning is a type of artificial intelligence implemented by using artificial neural networks with many layers to analyse and extract features from data, particularly complex matrices like images or text or even molecule structures. Deep learning, a subfield of machine learning that has gained popularity in the last decade due to its high success rates on problems such as image recognition, natural language processing and drug design [17]. AI technologies in drug discovery are used for all: target identification and validation, lead optimization, pre-clinical studies to clinical trials. There are a few ways AI can be implemented in to drug research, such as predicting new syndromes and their causes with deep learning models on health records; optimizing chemical structures for functions like protease inhibition using evolutionary algorithms; and streamlining experimental design & analysis (e.g. by analysing the nature/cause of symptom data from clinical trials) [18].

2.1 Application of AI in Drug Development

Sometimes, AI can predict how effective and safe a candidate drug will be instead of using traditional experimental methods which begin to reduce the time and cost. These machine learning models are trained on thousands or millions of chemical structures, biological assays, and clinical data sets to diagnose new drug candidates as well predict their probabilities in working form for perspective stages of development [19]. For instance, DL models have been applied to predict the binding affinity of drug molecules with target proteins which are essential in determining their therapeutic efficacy. In silico models based on artificial intelligence have been used to predict the absorption, distribution, metabolism excretion and toxicity (ADMET) profiles of drug candidates with impressive success in reducing or eliminating candidate compounds early during discovery. AI can also help with different parts of clinical trials as well, such patient recruitment data collection and interpretation, to monitoring adverse events [20]. By recognizing patterns throughout different patients (including genetics, disease characteristics or responses to treatment), machine-learning technologies could generate an algorithm that funnel the right patient base towards a drug [21]. Using AI, It can also help cloud both even the clinical trial design to minimized number of patients are thinner time longer than used for determining [22]. Deep learning systems can sift through gigabytes, terabytes and even petabytes of data from electronic health records (EHRs), wearables, patient reported outcomes to help detect trends or patterns that are not readily numbered by a human counterpart [23].

2.2 Challenges and Limitations of AI in Drug Discovery

AI could absolutely help revolutionize drug discovery HOWEVER there are limitations and obstacles to consider:

a. Data quality and Data quantity: The efficiency of AI algorithms is proportional to the presence of data diversity, along with a continuous inflow of solid datasets. Inadequate data or with bias may result in incorrect predictions and unsuitable drug-candidates [24].
b. Interpretability and explainability: The interpretively of AI models, especially deep learning models being complex in nature makes it difficult to understand the reason behind their predictions [25]. This lack of transparency creates an issue with the deployment of AI in drug discovery which requires some explanations to be labelled along with results.
c. There must be validation: like the process of regulatory approval, AI-generated drug candidates need to work safely and effectively in reality. This could slow the development of AI-driven drug discovery methods as regulatory agencies might ask for more evidence before approving them [26].
d. Ethical concerns: The implementation of AI in drug discovery process is an ethical issue such as data privacy, algorithmic bias, and the possibility of suffering from unforeseen consequences. This motivates the need to make sure AI is developed and deployed in a responsible an ethical way by researchers and pharmaceutical companies.

However, despite the challenges that stand in way of AI achieving its full potential for drug discovery if these are overcome, they can directly impact on more and better medicines being made available to patients with a range of diseases far quicker than we see today [27]. Due to the ongoing development of AI technologies and their increasing application in various fields, it becomes essential for scientific community and policy makers to collaboratively address issues impeding progress with AI used in drug discovery.

3. Intellectual Property Rights in Life Sciences

In the life sciences sector, especially in drug discovery and development, intellectual property rights (IPR) are central to ensuring that innovations can be protected. The IPR (Intellectual Property Rights) framework consists of several components like patents, copyrights, trademarks, trade secrets protecting interests in respect to inventions and creations. Prior to SOAPY, I co-founded a different startup that developed haemoglobin metrics for patient monitoring devices and addressed the epilepsy care continuum-Patents are the principal way new drug candidates can be protected so pharmaceutical companies may recover R&D costs. A patent gives the inventor exclusive right to prohibit others from making, using, or selling an invention for a set number of years (commonly 20) as defined by the filing date of the Patent Application [28]. Trade secrets Trade secret protection can also be taken against the disclosure of confidential information on drug discovery and development processes. Under the law, you can protect a trade secret as long as it remains confidential and gives an advantage in competition to its owner. In the life sciences sector, this legal regime of IPR influences laws from national countries and international treaties, such as TRIPS (the Agreement on Trade-Related Aspects of Intellectual Property Rights) implemented

by WTO. TRIPS requires member states to provide and maintain minimum standards of protection for various forms intellectual property rights, including copyrights, patents trademarks [29].

3.1 Patent Eligibility and Ownership Issues

The rapid adoption of AI in drug discovery has led to questions regarding the patentability, and more broadly ownership of results from this use. For example, the United Kingdom recently decided in Thaler v. Vidal court case that AI does not meet fundamental requirements for being considered an inventor under current patent laws [30]. The impact of the ruling had potentially serious implications for drug discovery in the life sciences industry, suggesting AI-discovered drugs would not be patentable and undermining a core incentive pharma must invest heavily in new approaches to developing drugs with machine-learning edit by Marina E. & David S - AI software. It is also unclear who should own claims to AI-generated inventions whether it be the owner of an AI, its developers, or anyone else providing data that underpin such intellectual property [31]. Policymakers and industry participants in the life sciences sector should discuss whether current IPR framework is adequately designed to protect AI-driven innovations, or required changes are needed under existing laws/ rules [32]. They could come in the form of new categories at inventors, like AI-assisted inventors or other kinds for which we will need to develop protection over inventions created.

3.2 Current Trends in IPR Related to AI Innovations

While addressing the challenges involved, several trends in life sciences are nevertheless pointing to ways for incorporating AI into IPR model where possible:

i. Collaborative Research and Development: AI drug discovery platforms call for increased collaboration between pharmaceutical companies, AI startups as well as research institutions. These partnerships enable to share data, knowledge, and resources as applicable while addressing concerns around IPR thereof through contractual frame [33].
ii. Defensive publication: instead of seeking patent protection for their AI inventions, companies may opt to defensively publish them. In exchange for their publication of the innovation, they keep anyone else from patenting that same invention as well; this in turn allows them to use it themselves.
iii. Trade secret dependence: Because the patentability of AI-generated inventions is uncertain, some companies may protect their proprietary drug discovery process using trade secrets [34]. This keeps them competitive while avoiding the risks of trying to file for patents.
iv. Calls for IPR reform: Some industry groups and legal scholars are calling to adapt the existing IPR framework crafted with human innovation in mind, for AI-driven innovations [35]. For example, these changes include broader scope of inventorship to encompass AI systems per se; new modes of protection for inventions generated by AIs and provisions on ownership and licensing when the relevant IP is in AI or was created based upon use thereof.

In view of the increasing uptake of AI technologies in life sciences, it is apparent that there will be a need to reform the current IPR framework based on new technological advancements. Through collaborative research, the use of alternative means to protect new findings and support for IPR reform, stakeholders can help ensure that AI-driven drug discovery is fully realised while at the same time maintaining a sound system of intellectual property protection [36].

4. Legal Implications of AI in Drug Discovery

Artificial Intelligence (AI) is increasingly becoming part of the pharmaceutical industry and these legal components are constantly complex. There are dozens of legal hurdles arising as AI algorithms help to streamline drug development processes, including crazy amounts of data indicating potential new drugs; predictions for their efficacy prior to extensive testing and optimal structure modifications [37]. A key concern relates to patent eligibility and ownership of AI-generated inventions. The current legal landscape does not definitively clarify whether AI can constitute an inventor, hence increasing doubt as to when a drug discovered via AI may be patentable. This very question came to a head in the landmark case Thaler vs. Vidal, that determined AI cannot be considered an inventor under U.S. patent law and whether pharmaceutical companies can patent drugs developed with help from AI or not? The murkiness could discourage companies to invest in AI-driven research if they have inadequate IP protections [38].

4.1 Liability Issues in AI-Generated Drugs

As AI gains traction in the drug discovery process, liability for any adverse effects from drugs generated by AI

has accordingly emerged as a major legal issue Finding out who is to blame when an AI-discovered drug hurts a patient helps not only justice being done (the victims get reparation), but also in maintaining public trust of the pharmaceutical industry [39]. In this field of AI-generated drugs, myriad potential scenarios could create liability: Errors or biases in AI algorithm: If the failure of a harmful drug is caused by mistakes made by an AI system, which due to that produces biased results, this may lead to liability under negligence and product liability as assessed against the company owning the developer of the AI solution [40]. Lack of testing or validation - If a pharmaceutical company pushes an AI-generated drug to market without adequate testing, it may be liable for not taking reasonable care in the means used to ensure that the product as approved would not cause unreasonable risk. Falsely says that AI is human: Additionally, if a pharma claims an AI system as the inventor on its own or tells patients they are communicating with AIs and not humans when indeed said communication was conducted by people who were trained/ working for these pharmaceuticals companies directly those acts could be considered fraudulent [41].

Pharmaceutical companies will need to develop rigorous testing and validation procedures for AI-generated drugs to reduce these liability risks [42]. Furthermore, guidelines from policymakers and regulatory authorities might need to be established in the event an adverse effect emerges with AI-generated drugs, given how intricate this area is.

4.2 Regulatory Compliance and Guidelines

The more AI-powered drug discovery capabilities evolve, so too do the regulatory agencies that have made moves to incorporate their use through guidelines (i.e., US FDA and EU EMA) for this area of pharmaceuticals [43]. This is to ensure that AI technologies are developed and used in a way that safe, effective, responsible manner while facilitating innovation without compromising patient safety. Areas of Regulatory Focus

- Data quality and privacy: Regulatory bodies are learning to insist on high-quality, diverse datasets that AI systems learn from which must also respect the legislation created around patient data collection such as HIPAA or GDPRA (General Data Protection Regulation).
- Transparency and explainability: Regulators are demanding more transparency
- Validation and approval: Governments are working on defining criteria to prove that a drug designed by AI is safe for use; they have begun setting benchmarks (based upon in vitro testing) you must hit before running clinical trials, which need to be successfully completed prior granting regulatory clearance [44].
- Kicking the tires: Regulatory agencies want pharmaceutical companies that use an AI-based tool to generate a drug profile or recommended dosage, for example, to independently evaluate their products' quality and safety while sending any threatening notifications they receive on down the line.

Pharmaceutical companies must take compliance very seriously and invest in substantial programs to make sure all employees are trained, fields of operation audited from time-to-time 3rd party or internal auditing teams with root-cause analysis for risk management. Companies should also communicate with regulatory authorities as early and often in the drug development process to ensure that their AI technologies meet requisite or at least accepted standards, which will avoid major delays where necessary approvals are required [45].

4.3 Case Studies on AI and IPR Conflicts

AI in drug discovery is increasingly being integrated into business models and some high-profile scenarios have shown the increasing challenges between AI and intellectual property rights (IPR), including:

a) Thaler v. Vidal (where the U.S. Court of Appeals for the Federal Circuit held that an AI system named DABUS cannot be identified as an inventor in a patent application because, under existing US Patent Law statues, "inventor" means only natural persons) As expected, this decision leaves more unanswered questions about the patentability of AI-generated inventions and ownership in relation to its intellectual property [46].
b) Artificial Intelligence and Inventorship: In another case, the U.S. Patent and Trademark Office (USPTO) refused a patent registration for an AI invention, arguing that no human inventor contributed to it. This ruling highlights the ongoing ambiguity in respect of whether AI-generated inventions are patentable, and emphasises a potential role for policy makers and regulators to provide further guidance [47].
c) Collaborative Research and Development: To deal with complexity relating to AI as well as IPR, a few pharmaceutical companies are entering into collaborative research & development (R& D) through

Artificial Intelligence startups or institutions. These partnerships can help with the sharing of data and expertise as well as resources, while addressing IPR concerns via contractual agreements & joint ownership arrangements [48].

d) As a defensive measure, some companies are opting to publish their AI-generated inventions instead of spending the time and money prosecuting them through patent offices in order to make it available for all without being able others taking out a monopolistic position on its use.

These case studies highlight that the crossroad of AI and IPR in drug discovery fields are complicated, dynamic areas for law which necessitate cooperation among different partners like pharmaceutical entities with producers of AIs as well as policy makers, regulators. Through collaboration to solve these problems and create transparent guidelines around the use of AI in drug discovery, we can unlock all that potential while upholding inventors' rights - an advances patients are safer [49].

5. Ethical Considerations in AI and Drug Development

Artificial intelligence (AI) technology becoming integrated into the drug discovery create and development processes is driving profound innovation and productivity gains of historic proportions. But this same opportunity is creating a new set of ethical considerations that life sciences stakeholders must work together to navigate [50]. For health AI, these necessarily involve carefully managing data privacy (which straddles quality assurance) and scrubbing derived datasets to ensure there is no algorithmic bias or unethical use of deep learning tech more broadly in the digital healthcare ecosystem.

5.1 Data Privacy and Patient Consent

Ethical considerations that arise from the use of AI in drug development. One of the most immediate ethical concerns raised by implementing AI within different stages such as RD, clinical trials or process the production line is related to questions around data privacy and patient consent. Parallel to this, AI algorithms use millions of human patient data that include genetic information and medical records along with trials results to recognize potential drug candidates relying on their safety profile or if they are going to work likewise look at how we assess clinical trial design [51]. The use of this data can be a boon to drug discovery and patient outcomes, but it also raises important privacy considerations. At the most basic level, patients have a right to know what will happen to their data and who is going to use it [52]. Failure to be able to explain FDA-approved indications in lay terms, failure of appropriate consent or failing to ensure protection against unauthorized access and misuse can all threaten patient data privacy-leading not only legal penalties for the pharmaceutical industry but also loss influential power of this sector [53]. To alleviate these issues, research companies must utilize data protection methods like anonymizing the data where possible and keep it secure using encryption practices while limiting access only for those completing legitimate investigations. Companies must also obtain informed consent from patients, provide information on what data is being collected and how it will be used as well as the risks/benefits of participating [54].

5.2 Bias and Fairness in AI Algorithm

Algorithmic Bias and Unfairness: The use of AI in drug development raises another key ethical issue, i.e. the risk that the algorithms are biased or unfair. AI models are only as good as the data they're trained on, and if those datasets reflect historical disparities or underrepresentation of specific groups-whether racial minorities, women or seniors-it leads to biased inferences. If not identified and mitigated, these biases are amplified by the AI system resulting in suboptimal drugs for specific patient populations [55]. If an AI algorithm is trained on a data set in which women or racial minorities are underrepresented, it might not recognize drug candidates that work best for these populations; or risks associated with the use of those drugs specific to such groups. This potentially results in the creation of less effective or even more harmful therapeutics for this patient group, ultimately increasing healthcare disparities [56].

For AI in pharma, that means the datasets used to train such systems should be diverse enough - and free of known biases. To be continued, as they also need to develop strict testing and validation strategies that help them recognize as well solve biases before utilizing AI systems in drug development. Companies should also establish dialogue with a variety of stakeholders, such as patient advocates and community leaders, to make sure the types of AI-guided drugs being developed are based on what all patients want or need [57].

5.3 Ethical Frameworks for AI in Healthcare

Robust ethical frameworks need to be developed so that there is an unethical and responsible transition of AI into

the realm of drug development [58]. These frameworks should be developed by a consortium of pharmaceutical companies, AI developers and users with relevant regulatory agencies as well as patient advocate groups and ethicists on an ongoing basis to stay current with new technologies. Some key ingredients of an ethical scaffolding for AI in drug discovery are:

a) When it comes to beneficence and non-maleficence declaration, AI systems should be built in a way that aims first for societal benefit with maximum reduction of possible harms [59].
b) Respect for autonomy: patients should be informed about AI use and able to refuse participation
c) Justice and fairness: AI-guided drugs should be developed and deployed such that all groups have fair access to benefits of the resulting therapies, without increasing racial or genetic discrimination [60].
d) Transparency and accountability: The use of artificial intelligence in drug development should be disclosed to the outside world, as well be followed by responsibility for any negative consequences and unintended effects.
e) Active monitoring and evaluation: the application of AI in drug development should be monitored regularly with any new ethical issues or potential negative impacts addressed as soon as possible [61].
f) Life Science Industry: There is a huge potential for AI in healthcare that will help drive innovation and advance patient well-being while maintaining stringent ethical safeguards around all applications [62].

Ultimately, while incorporating AI into drug development has the potential to transform life sciences, it can and does bring up important ethical questions that need thorough investigation. Prioritise data privacy, mitigate algorithmic bias and develop ethical frameworks to guide the responsible use of AI in healthcare Stakeholders should be ensured on balancing the benefits that this transformation can bring while simultaneously upholding fundamental rights and wellbeing for patients when infusing AI into drug development [63]. Finally, as the use of AI in drug discovery and development continues to grow, this powerful force for change presents an opportunity for life sciences companies to demonstrate responsible leadership that extends beyond their own internal practices [64].

6. The Intersection of AI, IPR and Ethical Concerns

In this context, the integration of artificial intelligence (AI) to drug discovery and development has revolutionized life sciences as it involves unrivalled opportunities for innovation. But, at the same time this transformative process is sandwiched between a nuanced interplay of Intellectual Property Rights (IPR) and Ethical issues which must be navigated responsibly. This section examines the interplay between creating opportunities for innovation and ensuring that ethical standards are upheld, how stakeholders might overcome these challenges, and suggestions regarding policy development that arises to promote responsible AI use in drug design [65].

6.1 Balancing Innovation with Ethical Standards

The rapid pace of development in AI for drug discovery touches on core issues surrounding the tension between innovation and ethics. This will have two sides; AI is perfectly set up to undertake radical changes in the way that drugs are brought to market, making things more efficient, cheaper and ultimately delivering better patient experiences. Lastly, there are also the ethical concerns with these technologies [66].

Innovations and Its Implications

AI can pore over large sets of data and deliver insights that help us find new disease targets or more personalized treatments. This progress has the power to unlock solutions for unmet medical needs, such as rare diseases and historically hard-to-solve conditions. But those ethical considerations - such as patient safety, data privacy and equitable access to treatments - must not be sacrificed in the quest for innovation. To illustrate take the use of AI in drug discovery, for which we need to feed our algorithms with large datasets that potentially identify individual patient data. Privacy and misuse of personal health information are a major concern here. The ethical standards must ensure that patient data is dealt with in a responsible fashion - being informed consent from the individuals whose phenotype is used. Without emphasizing ethics, use of AI in healthcare is doomed to fail at public acceptance.

Ethical Standards in AI Development

A proactive approach to ethical governance: As the industry looks to stay ahead of these developments, they should maintain an effective balance between innovation and adherence toward leading standards. This will involve setting out clear codes of ethics that give instructions on the way we manage these dilemmas when using AI in drug development. These principles should be:

i. Explainability - Sheds light on the decision making processes and allows everyone to see how decisions are made at all stages of AI/ML systems. Such transparency is necessary to foster trust between patients, healthcare providers and regulatory bodies.
ii. Definition: Stakeholders working on AI-powered drug development should have some degree of accountability for the results that their technology delivers. This includes making it clear who would be responsible in case of adverse events from an AI created drug.
iii. Equity: We must ensure AI innovations benefit all patient populations regardless of race, ethnicity or socio-economic status by ensuring this technology does not exacerbate disparities in healthcare. This could mean proactively sourcing diverse data sets to prevent algorithm bias and ensure that AI models are trained on balanced samples [67].

By placing these ethical standards in the forefront, we will fortify a system that promotes innovation and simultaneously protects patient rights.

6.2 The Role of Stakeholders in Addressing Concerns

The successful integration of AI in drug discovery requires the collaboration of various stakeholders, including pharmaceutical companies, regulatory agencies, healthcare providers, and patient advocacy groups. Each of these stakeholders plays a vital role in addressing the legal and ethical concerns associated with AI technologies.

Pharma Companies

Pharma companies are leading the way in AI powered drug development and need to be ministries of deploying ethics. That, of course, includes investment in strong data governance frameworks to maintain compliance with data privacy laws and ethical standards. To reduce algorithmic bias and increase the generalizability of AI-based insights, companies should further focus on diversity within their datasets. Also, pharmaceutical companies must participate in public discussions of ethics related to AI. Companies can build equity in openness and solicit feedback from patients and advocacy groups to determine that they are being responsible, ethical actors by communicating details on their operations.

Patient Advocacy Groups

Patient advocacy groups are a key interface between the pharmaceutical industry and society as whole. These groups could have provided valuable information into patient perspectives and guided ethical standards around AI in drug development. These groups can help those working on AI technologies to advocate for patient rights and the equal access of treatments throughout any conversation. Further, consumer bases can help educate themselves on what AI means in healthcare impacts through patient advocacy groups. These organisations can educate the world on data privacy, create important dialogue about the pros and cons of AI-driven treatments; giving transparency ultimately helps patients make better decisions surrounding their healthcare.

6.3 Recommendations for Policy Development

For policymakers to successfully address the complexities at the intersection of AI, IPR, and ethical considerations in drug discovery new policies that help encourage responsible use of this capacity for innovation are sorely needed. The following policy recommendations highlight important areas for development:

- Create Regulatory Pathways: Policymakers should team up with regulators to prepare crisp regulations for leveraging AI in drug development. These guidelines should include provisions around data privacy, algorithmic transparency, and accountability to ensure that AI technologies are developed responsibly.
- Drive Data Governance: Strong data governance is critical to protect patient data and comply with confidentiality requirements. We can have policymakers excel in promoting pharmaceutical companies to adopt data privacy protocols that focus on securing the quality of content and conduct ethical use for knowledge.
- Facilitate Collaboration: A collaboration amongst the stakeholders of AI in drug discovery is vital to handle those legal and ethical issues rising from that. Policymakers can play a role in promoting dialogue and information-sharing by encouraging partnerships among regulatory agencies, pharmaceutical companies, healthcare providers & patient advocacy groups.
- Foster Ethical AI Research: Policymakers must fund and promote research programs, exclusively meant for recognizing the ethical dimensions of AI applications in medical care. The findings from this research can be used to determine the best practices in AI and lay a foundational framework for ethical practice by which we should hold all applications of AI technology accountable especially when it comes to assisting pharmaceutical industries.

- Cultivate Public Engagement: The public needs to be engaged in the discourse on AI within drug discovery so they trust it and ethics are a central focus. Policymakers need to run large public information campaigns around the advantages and disadvantages of going down the AI path in healthcare
- Surveillance and Feedback Loops regarding AI Technologies: Policy makers should create systems for the ongoing surveillance, evaluation of AI technologies that are introduced in drug development. Evaluation of the impact on patient outcomes, detection/prevention of bias, and evaluation if ethics stand in test.

Implementing these suggestions would allow our policymakers to create the perfect environment for innovation and patient rights and welfare protection. Application of AI in drug discovery and the interplay with IPRs coupled with ethical considerations pose challenges, as well as possibilities at the intersection of science-business-society, underscoring a need for forward thinking policy development if we are to fully exploit AIs potential within life sciences.

7. Conclusion and Suggestions

The convergence of Artificial Intelligence (AI), Intellectual Property Rights (IPR) and Ethical issues in drug discovery & development is a gamechanger for combination across the life sciences industry. As AI technologies further shape the pharmaceutical landscape, they present a myriad of transformative possibilities and equally numerous complex issues. The paper culminates with this conclusion that combines all the learnings from different sections of the research, underscoring he importance to innovate drug development while at onboard legal and ethical dimensions. By making the drug discovery and development process more effective, AI not only drives down costs but speeds up time-to-market for new therapeutics. Nevertheless, this technology is not quite foolproof. Some points on the ethics of AI, including data privacy and algorithmic bias (plus transparency) need special attention. In fact, the dependence on massive datasets to train AI systems spurs serious questions around patient consent and protection of sensitive health data. Additionally, inherent biases in the data used to train these systems can result in unfair healthcare outcomes - potentially exacerbating health disparities among marginalized communities.

As the pharmaceutical industry continues to adopt AI, balancing a desire for innovation with ethical norms will be key. This necessitates an approach of AI with transparency, accountability, and equity from research to deployment. Together, stakeholders including pharmaceutical organizations, regulatory body officials and healthcare professionals along with patient advocacy groups should establish an ethical framework in regulating the application of AI driven automated pipelines for drug discovery. These stakeholders can collectively encourage an environment of open dialogue and accountability that can minimize ethical hazards to the greatest extent possible, maximizing AI benefits simultaneously. Stakeholders are key to addressing the complex challenges of AI in drug development. Pharmaceutical companies, however have a significant role in ensuring that the data governance framework is strong and more importantly, data sets diverse enough to reduce algorithmic bias. Regulatory agencies are responsible for establishing clear norms around the ethical application of AI tools, and advocates can have a unique understanding as to what patients want and which victories examples need. By involving all stakeholders, the industry can develop a holistic ethical AI framework that puts patient safety and equal access to treatment first. Policymakers will need to calibrate a complex balancing act in using AI responsibly across a framework of IPR, as well as addressing the ethical considerations that stem from it. They recommend policy development to identify regulatory frameworks, aspirational principles of effective data governance and collaboration among stakeholders as well as research on ethical ai advances; promote public engagement with the ongoing monitoring mechanisms. This will help to foster the ethical integration of AI in drug discovery and make sure that such technology is leveraged for its full potential responsibly. Through an emphasis on ethical concerns and stakeholder collaboration, the life sciences industry can leverage AI to drive transformation in ways that are also respectful of patient rights and welfare. As AI continues to revolutionize pharmaceuticals, all actors must come together in addressing the legal and ethical issues that arise from it so as not only realize the gains of AI technologies but also deliver them justly. Moving forward, dedication to ethical governance, transparency and responsibility is the responsible thing for safeguarding that innovation in drug development aligns with society.

References

1. Romanelli, V., Cerchia, C., & Lavecchia, A. (2024). Unlocking the potential of generative artificial intelligence in drug discovery. *Applications of Generative AI*, 37-63.

2. Bordukova, M., Makarov, N., Rodriguez-Esteban, R., Schmich, F., & Menden, M. P. (2024). Generative artificial intelligence empowers digital twins in drug discovery and clinical trials. *Expert Opinion on Drug Discovery*, *19*(1), 33-42.
3. Zhang, X., Sheng, Y., & Liu, Z. (2024). Using expertise as an intermediary: Unleashing the power of blockchain technology to drive future sustainable management using hidden champions. *Heliyon*, *10*(1).
4. Rani, P. (2022). Nanosensors and their Potential Role in Internet of Medical Things. In *Nanosensors for Futuristic Smart and Intelligent Healthcare Systems* (pp. 293-317). CRC Press.
5. Rubeis, G. (2024). Ethical implications of blockchain technology in biomedical research. *Ethik in der Medizin*, 1-14.
6. Singh, B., & Kaunert, C. (2024). Future of Digital Marketing: Hyper-Personalized Customer Dynamic Experience with AI-Based Predictive Models. *Revolutionizing the AI-Digital Landscape: A Guide to Sustainable Emerging Technologies for Marketing Professionals*, 189.
7. Singh, B., Kaunert, C., & Vig, K. (2024). Reinventing Influence of Artificial Intelligence (AI) on Digital Consumer Lensing Transforming Consumer Recommendation Model: Exploring Stimulus Artificial Intelligence on Consumer Shopping Decisions. In T. Musiolik, R. Rodriguez, & H. Kannan (Eds.), *AI Impacts in Digital Consumer Behavior* (pp. 141-169). IGI Global. https://doi.org/10.4018/979-8-3693-1918-5.ch006
8. Ahirwar, R., & Khan, N. (2022). *Smart Wireless Nanosensor Systems for Human Healthcare* (pp. 265-292). CRC Press.
9. Han, B., Tomer, V., Nguyen, T. A., Farmani, A., & Singh, P. K. (Eds.). (2020). *Nanosensors for smart cities*. Elsevier.
10. Rizwan, A., Zoha, A., Zhang, R., Ahmad, W., Arshad, K., Ali, N. A., ... & Abbasi, Q. H. (2018). A review on the role of nano-communication in future healthcare systems: A big data analytics perspective. *IEEE Access*, *6*, 41903-41920.
11. Pramanik, P. K. D., Solanki, A., Debnath, A., Nayyar, A., El-Sappagh, S., & Kwak, K. S. (2020). Advancing modern healthcare with nanotechnology, nanobiosensors, and internet of nano things: Taxonomies, applications, architecture, and challenges. *IEEE Access*, *8*, 65230-65266.
12. Archana, K., & Gloth, A. (2024). Blockchain and Entrepreneurship. In *Applying Business Intelligence and Innovation to Entrepreneurship* (pp. 35-51). IGI Global.
13. Nazari, A. (2020). Nanosensors for smart cities: an introduction. In *Nanosensors for smart cities* (pp. 3-8). Elsevier.
14. Sahi, K. S. S., & Kaushik, S. (2022). Smart Nanosensors for Healthcare Monitoring and Disease Detection using AIoT Framework. In *Nanosensors for Futuristic Smart and Intelligent Healthcare Systems* (pp. 387-400). CRC Press.
15. Oukhatar, A., Bakhouya, M., & El Ouadghiri, D. (2021). Electromagnetic-Based Wireless Nano-Sensors Network: Architectures and Applications. *J. Commun.*, *16*(1), 8.
16. Singh, B., & Kaunert, C. (2024). Salvaging Responsible Consumption and Production of Food in the Hospitality Industry: Harnessing Machine Learning and Deep Learning for Zero Food Waste. In *Sustainable Disposal Methods of Food Wastes in Hospitality Operations* (pp. 176-192). IGI Global.
17. Singh, B. (2024). Evolutionary Global Neuroscience for Cognition and Brain Health: Strengthening Innovation in Brain Science. In *Biomedical Research Developments for Improved Healthcare* (pp. 246-272). IGI Global.
18. Singh, B., Kaunert, C., & Vig, K. (2024). Reinventing Influence of Artificial Intelligence (AI) on Digital Consumer Lensing Transforming Consumer Recommendation Model: Exploring Stimulus Artificial Intelligence on Consumer Shopping Decisions. In *AI Impacts in Digital Consumer Behavior* (pp. 141-169). IGI Global.
19. Singh, B., & Kaunert, C. (2024). Revealing Green Finance Mobilization: Harnessing FinTech and Blockchain Innovations to Surmount Barriers and Foster New Investment Avenues. In *Harnessing Blockchain-Digital Twin Fusion for Sustainable Investments* (pp. 265-286). IGI Global.
20. Gao, Q. (2024). *Artificial Intelligence Governance and the Blockchain Revolution*. Springer Nature.
21. He, L., & Eastburn, M. (2022, August). Smart nanosensor networks for body injury detection. In *2022 IEEE International Conference on Smart Internet of Things (SmartIoT)* (pp. 15-19). IEEE.

22. Mujawar, M. A., Gohel, H., Bhardwaj, S. K., Srinivasan, S., Hickman, N., & Kaushik, A. (2020). Nano-enabled biosensing systems for intelligent healthcare: towards COVID-19 management. *Materials Today Chemistry*, *17*, 100306.
23. Omanović-Mikličanin, E., Maksimović, M., & Vujović, V. (2015). The future of healthcare: nanomedicine and internet of nano things. *Folia Medica Facultatis Medicinae Universitatis Saraeviensis*, *50*(1), 23-28.
24. Udoh, E. E., Hermel, M., Bharmal, M. I., Nayak, A., Patel, S., Butlin, M., & Bhavnani, S. P. (2023). Nanosensor technologies and the digital transformation of healthcare. *Personalized Medicine*, *20*(3), 251-269.
25. Shafik, W. (2024). Data-Driven Future Trends and Innovation in Telemedicine. In *Improving Security, Privacy, and Connectivity Among Telemedicine Platforms* (pp. 93-118). IGI Global.
26. Chelliah, R., Wei, S., Daliri, E. B. M., Rubab, M., Elahi, F., Yeon, S. J., ... & Oh, D. H. (2021). Development of nanosensors based intelligent packaging systems: food quality and medicine. *Nanomaterials*, *11*(6), 1515.
27. Topel, S. D., & Al-Turjman, F. (2019). Nanosensors for the internet of nano-things (IoNT): an overview. *Internet of Nano-Things and Wireless Body Area Networks (WBAN)*, 21-44.
28. Dinesh kumar, K. (2013, February). Human health monitoring mobile phone application by using the wireless nanosensor based embedded system. In *2013 International Conference on Information Communication and Embedded Systems (ICICES)* (pp. 889-892). IEEE.
29. Materon, E. M., Gómez, F. R., Joshi, N., Dalmaschio, C. J., Carrilho, E., & Oliveira Jr, O. N. (2021). Smart materials for electrochemical flexible nanosensors: advances and applications. *Nanosensors for smart manufacturing*, 347-371.
30. Kumar, S., & Kumari, P. (2021). Flexible Nano Smart sensors. *Nanosensors for Smart Manufacturing*, *199*.
31. Singh, B. (2024). Featuring Consumer Choices of Consumable Products for Health Benefits: Evolving Issues from Tort and Product Liabilities. *Journal of Law of Torts and Consumer Protection Law*, *7*(1), 53-56.
32. Singh, B. (2024). Social Cognition of Incarcerated Women and Children: Addressing Exposure to Infectious Diseases and Legal Outcomes. In K. Reddy (Ed.), *Principles and Clinical Interventions in Social Cognition* (pp. 236-251). IGI Global. https://doi.org/10.4018/979-8-3693-1265-0.ch014
33. Singh, B., & Kaunert, C. (2024). Harnessing Sustainable Agriculture Through Climate-Smart Technologies: Artificial Intelligence for Climate Preservation and Futuristic Trends. In *Exploring Ethical Dimensions of Environmental Sustainability and Use of AI* (pp. 214-239). IGI Global.
34. Gaobotse, G., Mbunge, E., Batani, J., & Muchemwa, B. (2022). Non-invasive smart implants in healthcare: Redefining healthcare services delivery through sensors and emerging digital health technologies. *Sensors International*, *3*, 100156.
35. Vivekananthan, V., Khandelwal, G., Alluri, N. R., & Kim, S. J. (2022). E-Skin for Futuristic Nanosensor Technology for the Healthcare System. In *Nanosensors for Futuristic Smart and Intelligent Healthcare Systems* (pp. 133-157). CRC Press.
36. Pradhan, M. R., Mago, B., & Ateeq, K. (2023). A classification-based sensor data processing method for the internet of things assimilated wearable sensor technology. *Cluster Computing*, *26*(1), 807-822.
37. Manogaran, G., Alazab, M., Song, H., & Kumar, N. (2021). CDP-UA: Cognitive data processing method wearable sensor data uncertainty analysis in the internet of things assisted smart medical healthcare systems. IEEE Journal of Biomedical and Health Informatics, 25(10), 3691-3699.
38. Suma, D. V. (2021). Wearable IoT based distributed framework for ubiquitous computing. *Journal of Ubiquitous Computing and Communication Technologies*, *3*(1), 23-32.
39. Jenkins, T. (2022). Wearable medical sensor devices, machine and deep learning algorithms, and internet of things-based healthcare systems in COVID-19 patient screening, diagnosis, monitoring, and treatment. American Journal of Medical Research, 9(1), 49-64.
40. Malik, A., & Kumar, A. (2022). assimilation of blockchain with Internet of Things (IoT) with possible issues and solutions for better connectivity and proper security. In New Trends and Applications in Internet of Things (IoT) and Big Data Analytics (pp. 187-207). Cham: Springer International Publishing.

41. Singh, B. (2023). Unleashing Alternative Dispute Resolution (ADR) in Resolving Complex Legal-Technical Issues Arising in Cyberspace Lensing E-Commerce and Intellectual Property: Proliferation of E-Commerce Digital Economy. *Revista Brasileira de Alternative Dispute Resolution-Brazilian Journal of Alternative Dispute Resolution-RBADR*, *5*(10), 81-105.
42. Kumar, P. M., Khan, L. U., & Hong, C. S. (2022). Affirmative fusion process for improving wearable sensor data availability in artificial intelligence of medical things. IEEE Sensors Journal.
43. Han, X. (2023). A novel assimilated navigation model based on advanced optical systems (AOS), internet of things (IoT) and artificial intelligence (AI). Optical and Quantum Electronics, 55(7), 655.
44. Dash, D., Farooq, R., Panda, J. S., & Sandhyavani, K. V. (2019). Internet of Things (IoT): The New Paradigm of HRM and Skill Development in the Fourth Industrial Revolution (Industry 4.0). IUP Journal of Information Technology, 15(4).
45. Goethals, I. (2019). Real-time and remote health monitoring Internet of Things-based systems: Digital therapeutics, wearable and implantable medical devices, and body sensor networks. American Journal of Medical Research, 6(2), 43-48.
46. Banerjee, A., Chakraborty, C., & Rathi Sr, M. (2020). Medical imaging, artificial intelligence, internet of things, wearable devices in terahertz healthcare technologies. In Terahertz biomedical and healthcare technologies (pp. 145-165). Elsevier.
47. Barnes, R., & Zvarikova, K. (2021). Artificial intelligence-enabled wearable medical devices, clinical and diagnostic decision support systems, and Internet of Things-based healthcare applications in COVID-19 prevention, screening, and treatment. American Journal of Medical Research, 8(2), 9-22.
48. Singh, B. (2023). Blockchain Technology in Renovating Healthcare: Legal and Future Perspectives. In *Revolutionizing Healthcare Through Artificial Intelligence and Internet of Things Applications* (pp. 177-186). IGI Global.
49. Desai, D., & Shende, P. (2021). Integration of Internet of Things with Quantum Dots: A State-of-the-art of Medicine. Current Pharmaceutical Design, 27(17), 2068-2075.
50. Hurley, D., & Popescu, G. H. (2021). Medical big data and wearable internet of things healthcare systems in remotely monitoring and caring for confirmed or suspected COVID-19 patients. American Journal of Medical Research, 8(2), 78-90.
51. Singh, D., Divan, M., & Singh, M. (2022). Internet of things for smart community solutions. Sensors, 22(2), 640.
52. Tsang, Y. P., Choy, K. L., Wu, C. H., Ho, G. T., Lam, C. H., & Koo, P. S. (2018). An Internet of Things (IoT)-based risk monitoring system for managing cold supply chain risks. Industrial Management & Data Systems, 118(7), 1432-1462.
53. Goel, S. S., Goel, A., Kumar, M., & Moltó, G. (2021). A review of Internet of Things: qualifying technologies and boundless horizon. Journal of Reliable Intelligent Environments, 7, 23-33.
54. Kumar, P. M., Khan, L. U., & Hong, C. S. (2022). Notice of Violation of IEEE Publication Principles: Affirmative Fusion Process for Improving Wearable Sensor Data Availability in Artificial Intelligence of Medical Things. IEEE Sensors Journal.
55. Huang, J., Wu, X., Huang, W., Wu, X., & Wang, S. (2021). Internet of things in health management systems: A review. International Journal of Communication Systems, 34(4), e4683.
56. Malik, P. K., Sharma, R., Singh, R., Gehlot, A., Satapathy, S. C., Alnumay, W. S., ... & Nayak, J. (2021). Industrial Internet of Things and its applications in industry 4.0: State of the art. Computer Communications, 166, 125-139.
57. Kumar, P. M., Hong, C. S., Afghah, F., Manogaran, G., Yu, K., Hua, Q., & Gao, J. (2021). Clouds proportionate medical data stream analytics for internet of things-based healthcare systems. IEEE Journal of Biomedical and Health Informatics, 26(3), 973-982.
58. Kavre, M., Gadekar, A., & Gadhade, Y. (2019, December). Internet of Things (IoT): a survey. In 2019 IEEE pune section international conference (PuneCon) (pp. 1-6). IEEE.
59. Javaid, M., & Khan, I. H. (2021). Internet of Things (IoT) enabled healthcare helps to take the challenges of COVID-19 Pandemic. Journal of oral biology and craniofacial research, 11(2), 209-214.

60. Mukati, N., Namdev, N., Dilip, R., Hemalatha, N., Dhiman, V., & Sahu, B. (2023). Healthcare assistance to COVID-19 patient using internet of things (IoT) enabled technologies. Materials today: proceedings, 80, 3777-3781.
61. Singh, B. (2024). Lensing Legal Dynamics for Examining Responsibility and Deliberation of Generative AI-Tethered Technological Privacy Concerns: Infringements and Use of Personal Data by Nefarious Actors. In A. Ara & A. Ara (Eds.), *Exploring the Ethical Implications of Generative AI* (pp. 146-167). IGI Global. https://doi.org/10.4018/979-8-3693-1565-1.ch009
62. Singh, B., Vig, K., & Kaunert, C. (2024). Modernizing Healthcare: Application of Augmented Reality and Virtual Reality in Clinical Practice and Medical Education. In Modern Technology in Healthcare and Medical Education: Blockchain, IoT, AR, and VR (pp. 1-21). IGI Global.
63. Singh, B. & Kaunert, C. (2024). Salvaging Responsible Consumption and Production of Food in the Hospitality Industry: Harnessing Machine Learning and Deep Learning for Zero Food Waste. In A. Singh, P. Tyagi, & A. Garg (Eds.), *Sustainable Disposal Methods of Food Wastes in Hospitality Operations* (pp. 176-192). IGI Global. https://doi.org/10.4018/979-8-3693-2181-2.ch012
64. Zhang, Z., Wen, F., Sun, Z., Guo, X., He, T., & Lee, C. (2022). Artificial intelligence-enabled sensing technologies in the 5G/internet of things era: from virtual reality/augmented reality to the digital twin. Advanced Intelligent Systems, 4(7), 2100228.
65. Rejeb, A., Rejeb, K., Treiblmaier, H., Appolloni, A., Alghamdi, S., Alhasawi, Y., & Iranmanesh, M. (2023). The Internet of Things (IoT) in healthcare: Taking stock and moving forward. Internet of Things, 100721.
66. Aceto, G., Persico, V., & Pescapé, A. (2020). Industry 4.0 and health: Internet of things, big data, and cloud computing for healthcare 4.0. Journal of Industrial Information Integration, 18, 100129.
67. Singh, B. (2023). Blockchain Technology in Renovating Healthcare: Legal and Future Perspectives. In *Revolutionizing Healthcare Through Artificial Intelligence and Internet of Things Applications* (pp. 177-186). IGI Global.